A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer
The primary objective will be to determine the progression-free survival as per im une-related RECIST (ir ECIST) among subjects with metastatic urothelial cancer (mUC) treated with pembrolizumab versus placebo as maintenance therapy after 4-6 cycles of first-line chemotherapy.
Study Number: 

I 279815

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.